Understand the source comparison
Pe-22-28 Science Explained: Comparison of GHRH Analogs
Research teams selecting growth hormone secretagogues face multiple structural classes—each with distinct receptor mechanisms, half-lives, and signaling profiles. The table below compares Pe-22-28 against native GHRH, sermorelin (another GHRH analog), and grow
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research teams selecting growth hormone secretagogues face multiple structural classes—each with distinct receptor mechanisms, half-lives, and signaling profiles. The table below compares Pe-22-28 against native GHRH, sermorelin (another GHRH analog), and growth hormone releasing peptides (GHRPs) to clarify when each compound offers specific advantages.
- Pe-22-28
- GHRH receptor agonist; activates adenylyl cyclase → cAMP → PKA → GH gene transcription
- 60–90 minutes
- Proteolytic resistance via N-terminal modifications; sustained receptor occupancy
- Optimal for protocols requiring extended GH elevation without axis suppression; 5–7× longer half-life than native GHRH
- Native GHRH (1-44)
- GHRH receptor agonist; identical signaling to Pe-22-28 but rapid DPP-4 degradation
- <10 minutes
- Exact physiological signaling profile; no structural modifications
- Limited research utility due to rapid clearance; requires continuous infusion for sustained effect
- Sermorelin (GHRH 1-29)
- GHRH receptor agonist; truncated sequence retains full activity but lacks C-terminal stability
- 10–20 minutes
- FDA approval history for diagnostic use; well-characterized safety profile
- Intermediate duration between native GHRH and Pe-22-28; insufficient half-life for single-dose protocols
- GHRP-6 / GHRP-2
- Ghrelin receptor agonist (growth hormone secretagogue receptor 1a); stimulates GH release via distinct receptor
- 20–30 minutes
- Synergistic effect when combined with GHRH analogs; also increases appetite and gastric motility
- Different receptor mechanism allows combination protocols; less specific than GHRH for isolated GH stimulation
- CJC-1295
- GHRH analog with drug affinity complex (DAC) modification; binds albumin to extend half-life
- 6–8 days
- Once-weekly dosing due to extreme half-life extension
- Prolonged elevation risks disrupting natural GH pulsatility; associated with antibody development in some studies
- Pe-22-28 occupies a middle position—longer-acting than native GHRH and sermorelin, shorter-acting than CJC-1295. This duration profile preserves natural pulsatile GH secretion patterns while providing sufficient duration for measurable downstream effects. Research designs requiring daily dosing benefit from Pe-22-28's pharmacokinetic window, which allows once-daily administration without accumulation or axis suppression.